是β连接素中和交涉由珠单抗作用调节的机制？

Title:Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?

Volume: 15 Issue: 10

Author(s): M. Galuppo, E. Mazzon, S. Giacoppo, O. Bereshchenko, S. Bruscoli, C. Riccardi and P. Bramanti

Affiliation:

关键词: 复发/多发性硬化缓解，第一个患者诊断，细胞外 /β-连环信号通路，那他珠单抗，β-干扰素

摘要: Aberrant activation of Wnt/β-catenin signaling pathway is commonly associated to cancer development. However, molecular mechanisms controlling Wnt/β-catenin signaling pathway have been clarified only in part. Here, we show that β-catenin is differently modulated in patients with multiple sclerosis (MS), displaying that different pharmacological treatments used for clinical MS management cause different nuclear expression levels of β-catenin. Proteins extracted by peripheral blood mononuclear cells were assessed to evaluate the western blot expression levels of β-catenin. Analyzing our results, we realized that β-catenin is totally inhibited by Natalizumab and could have a role in MS management. This could offer new promising studies focused on the possible therapeutic control of β-catenin translocation.

Cite this article as:

M. Galuppo, E. Mazzon, S. Giacoppo, O. Bereshchenko, S. Bruscoli, C. Riccardi and P. Bramanti , Is β-catenin neutralization cross-involved in the mechanisms mediated by natalizumab action?, Current Molecular Medicine 2015; 15 (10) . https://dx.doi.org/10.2174/1566524016666151123114825